5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert- Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2- ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643) - A potent FLAP inhibitor suitable for topical administration

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 15, 2010, Pages 4598-4601

  Stock, Nicholas ^a   Baccei, Christopher ^a   Bain, Gretchen ^a   Chapman, Charles ^a   Correa, Lucia ^a   Darlington, Janice ^a   King, Christopher ^a   Lee, Catherine ^a   Lorrain, Daniel S ^a   Prodanovich, Pat ^a   Santini, Angelina ^a   Schaab, Kevin ^a   Evans, Jilly F ^a   Hutchinson, John H ^a   Prasit, Peppi ^a  

^a Amira Pharmaceuticals   (United States)

Author keywords

FLAP; Inhibitor; Leukotrienes

Indexed keywords

3 [3 TERT BUTYLSULFANYL 1 [4 (5 METHOXY PYRIMIDIN 2 YL) BENZYL] 5 (5 METHYL PYRIDIN 2 YLMETHOXY) 1H INDOL 2 YL] 2,2 DIMETHYL PROPIONIC ACID; AM 643; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONIC ACID; CYTOCHROME P450; DERMATOLOGICAL AGENT; ENZYME INHIBITOR; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PROTEIN BINDING; EAR DISEASE; EDEMA; ERYTHEMA; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NEUTROPHIL; NONHUMAN; RAT; SKIN DISEASE; SWELLING;

5-LIPOXYGENASE-ACTIVATING PROTEINS; ADMINISTRATION, TOPICAL; ANIMALS; ENZYME INHIBITORS; HUMANS; INDOLES; LEUKOTRIENES; MICE; PROPIONIC ACIDS; RATS; SKIN DISEASES;

MURINAE;

EID: 77955427072     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.06.011     Document Type: Article

References (27)

1. R.A.F. Dixon, R.E. Diehl, E. Opas, E. Rands, P.J. Vickers, J.F. Evans, J.W. Gillard, and D.K. Miller Nature 343 1990 282
2. J.F. Evans, A.D. Ferguson, R.T. Mosley, and J.H. Hutchinson Trends Pharmacol. Sci. 29 2008 72
3. K.R. Lynch, G.P. O'Neill, Q. Liu, D.-S. Im, N. Sawyer, K.M. Metters, N. Coulombe, M. Abramovitz, D.J. Figueroa, Z. Zeng, B.M. Connolly, C. Bai, C.P. Austin, A. Chateauneuf, R. Stocco, G.M. Greig, S. Kargman, S.B. Hooks, E. Hosfield, D.L. Williams Jr, A.W. Ford-Hutchinson, C.T. Caskey, and J.F. Evans Nature 399 1999 789
4. C.E. Heise, B.F. O'Dowd, D.J. Figueroa, N. Sawyer, T. Nguyen, D-S. Im, R. Stocco, J.N. Bellefeuille, M. Abramovitz, R. Cheng, D.L. Williams Jr., Z. Zeng, Q. Liu, L. Ma, M.K. Clements, N. Coulombe, Y. Liu, C.P. Austin, S.R. George, G.P. O'Neill, K.M. Metters, K.R. Lynch, and J.F. Evans J. Biol. Chem. 275 2000 30531
5. T.C. Beller, A. Maekawa, D.S. Friend, K.F. Austen, and Y. Kanaoka J. Biol. Chem. 279 2004 46129
6. P. Ciana, M. Fumagalli, M.L. Trincavelli, C. Verderio, P. Rosa, D. Lecca, S. Ferrario, C. Parravicini, V. Capra, P. Gelosa, U. Guerrini, S. Belcredito, M. Cimino, L. Sironi, E. Tremoli, G.E. Rovati, C. Martini, and M.P. Abbracchio EMBO 25 2006 4615
7. Y. Nonaka, T. Hiramoto, and N. Fujita Biochem. Biophys. Res. Commun. 337 2005 281
8. A. Maekawa, Y. Kanaoka, X. Xing, and K.F. Austen PNAS 105 2008 16695
9. R.D.R. Camp, J.R. Russell, D. Brain, and P.M. Wollard J. Invest. Dermatol. 82 1984 202
10. N.A. Soter, R.A. Lewis, E.J. Corey, and K.F. Austen J. Invest. Dermatol. 80 1983 115
11. K.F. Austen, A. Maekawa, Y. Kanaoka, and J.A. Boyce J. Allergy Clin. Immunol. 124 2009 406
12. For a review on leukotrienes and prostaglandins in psoriasis see: K. Ikai J. Dermatol. Sci. 21 1999 135
13. R.A. Hilger, K. Neuber, and W. König Immunology 74 1991 689
14. D.P. Woodmansee, and R.P. Simon Ann. Allergy Asthma Immunol. 83 1999 548
15. D.J. Yanase, and K. David-Bajar J. Am. Acad. Dermatol. 44 2001 89
16. M.H. Ellis J. Allergy Clin. Immunol. 102 1998 876
17. M.L. Pacor, G. Di Lorenzo, and R. Corrocher Clin. Exp. Allergy 31 2001 1607
18. N. Scuderi, M. Mazzocchi, P. Fioramonti, and G. Bistoni Aesthet. Plast. Surg. 30 2006 513
19. C.C. Zouboulis, S. Nestoris, Y.D. Adler, M. Orth, C.E. Orfanos, M. Picardo, E. Camera, and W. Cunliffe J. Arch. Dermatol. 139 2003 668
20. J.H. Hutchinson, Y. Li, J.M. Arruda, C. Baccei, G. Bain, C. Chapman, L. Correa, J. Darlington, C.D. King, C. Lee, D. Lorrain, P. Prodanovich, H. Rong, A. Santini, N. Stock, P. Prasit, and J.F. Evans J. Med. Chem. 52 2009 5803
21. N. Stock, C. Baccei, G. Bain, A. Broadhead, C. Chapman, J. Darlington, C. King, C. Lee, Y. Li, D.S. Lorrain, P. Prodanovich, H. Rong, A. Santini, J. Zunic, J.F. Evans, J.H. Hutchinson, and P. Prasit Bioorg. Med. Chem. Lett. 20 2010 213
22. Stock, N. S.; Zunic, J.; Li, Y.; Arruda. J.; Roppe, J.; Bain, G.; Santini, A.; Darlington, J.; King, C. D.; Baccei, C.; Lee, C.; Rong, H.; Chapman, C.; Broadhead, A.; Lorrain, D.; Correa, L.; Hutchinson, J. H.; Evans, J. F.; Prasit, P. J. Med. Chem., manuscript in review.
23. C. Brideau, C. Chan, S. Charleson, D. Denis, J.F. Evans, A.W. Ford-Hutchinson, J.H. Hutchinson, T.R. Jones, S. Léger, J.A. Mancini, C.S. McFarlane, C. Pickett, H. Piechuta, P. Prasit, D. Riendeau, C.A. Rouzer, P. Tagari, P.J. Vickers, R.N. Young, and W.M. Abraham Can. J. Physiol. Pharmacol. 70 1992 799
24. The details of this potency increase in blood for FLAP inhibitors will be published in due course. Bain, G. et al.
25. J.M. Young, D.A. Spires, C.J. Bedord, B. Wagner, S.J. Ballaron, and L.M. De Young J. Invest. Dermatol. 82 1984 367
26. J.H. Draize, G. Woodard, and H.D. Calvery J. Pharmacol. Exp. Ther. 83 1944 377
27. Draize, J. H. Association of food and drug officials of the United States, Texas State Dept. of Health, 1959.